Medical Management of Alcohol Abuse Disorder with Elevated Liver Enzymes

Immediate Management of Alcohol Withdrawal Syndrome (AWS)

Benzodiazepines are the gold standard treatment for AWS, with lorazepam being the preferred benzodiazepine for patients with liver dysfunction due to its shorter half-life and lack of active metabolites 1, 2
Short and intermediate-acting benzodiazepines, such as lorazepam, are safer in patients with hepatic dysfunction compared to long-acting ones, such as diazepam and chlordiazepoxide 2

Thiamine supplementation is crucial to prevent Wernicke encephalopathy, with a recommended dosage of 100-300 mg/day for 4-12 weeks 1, 3
Thiamine should be given before administering any glucose-containing IV fluids to prevent precipitating acute thiamine deficiency 1

Baclofen is the preferred medication for patients with alcoholic liver disease, as it has demonstrated safety and efficacy in promoting alcohol abstinence in patients with liver cirrhosis 1, 4, 5
Baclofen effectively reduces alcohol craving and helps maintain abstinence, with a recommended treatment period of several months 1, 2

Acamprosate may be considered as an alternative to baclofen, as it reduces withdrawal effects and craving for alcohol, with a recommended dosage of 1,998 mg/day for patients ≥60 kg 1, 3
Topiramate has shown promise in reducing heavy drinking and may decrease liver enzyme levels, but has not been specifically tested in patients with alcoholic liver disease 4, 6

Alcohol abstinence is the most important treatment for alcoholic liver disease, as it improves survival and prevents progression to cirrhosis, and should be combined with pharmacotherapy and psychosocial interventions 1, 3, 7
Monitor liver function tests regularly to assess improvement and medication effects 4

Naltrexone is not recommended for patients with alcoholic liver disease due to risk of hepatotoxicity 1, 3
Disulfiram should be avoided in patients with severe alcoholic liver disease due to possible hepatotoxicity 4, 6
Benzodiazepines should not be used beyond 10-14 days of treatment due to potential for abuse 2

The French Association for the Study of the Liver guidelines note that topiramate and gabapentin have shown effectiveness in treating alcohol use disorder, though their tolerance profile requires careful benefit-risk assessment 8
The European Association for the Study of the Liver guidelines identify gabapentin as a promising medication under preliminary research for alcohol withdrawal syndrome 9

Patients with current alcohol dependence who cannot access or tolerate FDA-approved medications, particularly those with liver disease, may benefit from gabapentin 8, 9

In patients with alcoholic liver disease, gabapentin offers distinct advantages, including no hepatotoxicity risk unlike naltrexone 9
Gabapentin is safe in severe liver disease, unlike disulfiram 9

The American College of Physicians recommends gabapentin as a second-line treatment for alcohol dependence, particularly in patients with liver disease or when first-line treatments are contraindicated, with optimal dose-dependent efficacy at 1800 mg/day 10
Gabapentin demonstrates a significant linear effect on complete abstinence rates: 4.1% (placebo) vs 11.1% (900 mg) vs 17.0% (1800 mg), with a p-value of 0.04 10
The number needed to treat (NNT) for abstinence is 8 and for non-excessive drinking is 5 at a dose of 1800 mg 10
Gabapentin improves symptoms related to relapse in a dose-dependent manner, including insomnia, dysphoria/mood, and craving (envie impérieuse) 10

The optimal dose of gabapentin is 1800 mg/day (600 mg three times a day), demonstrating the best efficacy in the reference clinical trial 10
The treatment duration should be at least 12 weeks, according to efficacy data, although guidelines generally suggest 3-6 months for alcohol dependence treatment 10

Gabapentin has a favorable safety profile, with no serious drug-related adverse events in the main trial and a similar rate of discontinuation due to adverse effects as placebo (9/150 participants) 10
Gabapentin is safe in cases of severe liver disease, unlike other options 10

Gabapentin should always be combined with psychosocial interventions, such as cognitive-behavioral therapy, motivational interviewing, and structured counseling 10
This combination of pharmacotherapy and psychotherapy demonstrates superior efficacy compared to usual care alone 10